Research Articles | Page 3 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria May 2021 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria: Where are we going May 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria Apr 2021 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia Jul 2023 Annals of Hematology Aplastic Anemia
Quality of life after immune suppressive therapy in aplastic anemia Apr 2024 Annals of Hematology Aplastic Anemia
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion Oct 2019 Annals of Hematology Myelodysplastic Syndromes (MDS)
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry Jul 2020 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Oct 2023 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Evolving therapies for lower-risk myelodysplastic syndromes Apr 2020 Annals of Hematology Myelodysplastic Syndromes (MDS)